Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agenus Inc.

www.agenusbio.com

Latest From Agenus Inc.

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Business Strategies Commercial

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.

Deals Financing

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies

Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot

Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Liposomes
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Antigenics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Agenus Inc.
  • Senior Management
  • Garo H Armen, PhD, Chmn. & CEO
    Alex Duncan, PhD, CTO
    Julie DeSander, VP, Bus. Dev. & Alliance Mngmt.
    Jennifer Buell, PhD, COO
    Christine Klaskin, VP, Fin.
  • Contact Info
  • Agenus Inc.
    Phone: (781) 674-4400
    3 Forbes Rd.
    Lexington, MA 02421-7305
    USA
UsernamePublicRestriction

Register